Log in

Compugen Stock Price, News & Analysis (NASDAQ:CGEN)

$4.04
+0.03 (+0.75 %)
(As of 10/23/2019 06:24 AM ET)
Today's Range
$3.98
Now: $4.04
$4.14
50-Day Range
$3.72
MA: $4.11
$4.49
52-Week Range
$2.00
Now: $4.04
$4.50
Volume54,463 shs
Average Volume85,585 shs
Market Capitalization$207.21 million
P/E RatioN/A
Dividend YieldN/A
Beta2.6
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGEN
CUSIPN/A
Phone972-3765-8585

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.80 million
Book Value$0.73 per share

Profitability

Net Income$-22,600,000.00

Miscellaneous

Employees89
Market Cap$207.21 million
Next Earnings Date11/11/2019 (Confirmed)
OptionableOptionable

Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.


Compugen (NASDAQ:CGEN) Frequently Asked Questions

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) released its earnings results on Monday, August, 5th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.04. View Compugen's Earnings History.

When is Compugen's next earnings date?

Compugen is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Compugen.

How can I listen to Compugen's earnings call?

Compugen will be holding an earnings conference call on Monday, November 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for CGEN?

1 equities research analysts have issued 1 year target prices for Compugen's stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Compugen's stock price to reach $9.00 in the next year. This suggests a possible upside of 122.8% from the stock's current price. View Analyst Price Targets for Compugen.

What is the consensus analysts' recommendation for Compugen?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Compugen.

Has Compugen been receiving favorable news coverage?

News stories about CGEN stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Compugen earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Compugen.

Who are some of Compugen's key competitors?

What other stocks do shareholders of Compugen own?

Who are Compugen's key executives?

Compugen's management team includes the folowing people:
  • Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 52)
  • Mr. Ari Krashin, Chief Financial & Operating Officer (Age 46)
  • Dr. John J. Hunter Ph.D., Chief Scientific Officer (Age 56)
  • Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 50)
  • Dr. Zurit Levine, Sr. VP of Technology Innovation (Age 51)

Who are Compugen's major shareholders?

Compugen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Rothschild Investment Corp IL (0.65%) and Defender Capital LLC. (0.58%).

Which major investors are selling Compugen stock?

CGEN stock was sold by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL and Defender Capital LLC..

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $4.04.

How big of a company is Compugen?

Compugen has a market capitalization of $207.21 million and generates $17.80 million in revenue each year. The biotechnology company earns $-22,600,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. Compugen employs 89 workers across the globe.View Additional Information About Compugen.

What is Compugen's official website?

The official website for Compugen is http://www.cgen.com/.

How can I contact Compugen?

Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]


MarketBeat Community Rating for Compugen (NASDAQ CGEN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  463
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: Buy-Side Analysts

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel